secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001104659-25-111484
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus recasts FY 2024/2023 financials for UDENYCA divestiture as discontinued operations
--------------------------------------------------------------------------------

- UDENYCA sale to Intas completed April 11, 2025 for $483.4M upfront cash including $118.4M inventory.
- Company eligible for two additional $37.5M earn-out payments.
- Recast financials for FY 2024 and 2023 show biosimilar businesses (UDENYCA, YUSIMRY, CIMERLI) as discontinued operations.
- Recast is for incorporation into a Form S-3 registration statement filed Nov 13, 2025.
- No other events after 2024 10-K filing are reflected except discontinued ops presentation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000110465925111484/0001104659-25-111484-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000110465925111484/chrs-20251113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-111484

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer